![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/neotx-announces-successful-first-stage-completion-of-its-phase-2a-clinical-trial-of-naptumomab-estafenatox-nap-in-combination-with-docetaxel-in-advanced-non-small-cell-lung-cancer-nsclc-301558939.html
https://www.prnewswire.com/news-releases/neotx-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancers-36th-annual-meeting-301419547.html
https://www.prnewswire.com/news-releases/neotx-announces-first-patient-enrolled-in-phase-2a-clinical-trial-of-naptumomab-estafenatox-nap-its-lead-tumor-targeted-superantigen-tts-candidate-in-combination-with-docetaxel-in-patients-with-advanced-non-small-cell-lung-c-301404001.html
https://www.globenewswire.com/news-release/2021/07/07/2259408/0/en/NeoTX-Hosting-Key-Opinion-Leader-Webinar-on-Overcoming-Check-Point-Inhibitor-Resistance.html
https://www.pharmacompass.com/pdf/news/us-fda-clears-neotxs-ind-application-for-ph-2-trial-of-naptumomab-estafenatox-1622781642.pdf